Eurand: Represented this Amsterdam-based specialty pharmaceutical company in its $123 million IPO.

Synageva BioPharma Corp.: Represented the underwriters, led by Goldman, Sachs & Co., in a $308 million offering of Synageva’s common stock.

Teva Pharmaceutical Industries Ltd.: Represented Teva, the leading generic pharmaceutical company in the world with a large specialty medicines business, in the following offerings:

• Three multi-tranche, multi-market offerings of senior notes aggregating $20.4 billion to finance its pending acquisition of Actavis Generics, the worldwide generic pharmaceutical business of Allergan plc.
• $6.75 billion aggregate stock offerings supporting its pending acquisition of Actavis Generics.
• €2 billion multi-tranche Eurobond offering.
• $1.3 billion debt tender offer for five series of senior notes.

Teva Pharmaceutical Industries Ltd.: Represented Teva, the leading generic pharmaceutical company in the world with a large specialty medicines business, in:

• $33.75 billion acquisition financing commitment, whereby the lenders have committed to provide Teva (i) up to $27 billion in loans under a senior unsecured Bridge Loan Credit Facility and (ii) up to $6.75 billion in loans under an Equity Bridge Loan Credit Facility.
• $1.0 billion five-year term loan facility.

• Confidential matters providing opinions and strategic advice on biosimilar patents
• Genentech v. Pfizer (D. Del.) (Herceptin) (trastuzumab) (pending)
• Amgen v. Hospira (D. Del.) (Epogen) (erythropoietin) (split decision in first U.S. jury trial under BPCIA; post-trial briefing pending)
• Amgen v. Hospira (Fed. Cir.) (Epogen) (erythropoietin) (favorable decision upholding district court on BPCIA issue of first impression)
• Hospira v. Genentech (USPTO) (Avastin) (bevacizumab) (favorable PTAB IPR decision)
• Hospira v. Genentech (USPTO) (Protein A chromatography) (favorable PTAB IPR decision)
• Takeda v. Array Biopharma (USPTO) (appeal pending after favorable IPR decision)
• Merck v. Hospira (D. Del.) (Invanz) (ertapenem) (appellate decision affirming favorable trial decision)
• Par v. Hospira (D. Del.) (Adrenalin) (epinephrine) (pending)
• Belcher v. Hospira (D. Del.) (Epinephrine Injection USP) (epinephrine) (pending)
• Vivus v. Actavis (D. Del.) (Qsymia) (pherntermine/ topiramate) (settled)
• Merck v. Amneal (Fed. Cir.) (Nasonex) (mometasone) (pending)
• Millennium Pharms. v. Sandoz and Hospira (Fed. Cir.) (Velcade) (bortezomib) (pending)
• Purdue v. Amneal (Fed. Cir.) (OxyContin) (oxycodone) (judgment of invalidity affirmed)
• Allergan v. UCB (E.D. Tex.) (Neupro) (rotigotine) (settled)
• Hospira v. Eurohealth (D. Del.) (Precedex) (dexmedetomidine) (settled)
• Hospira v. Intas (M.D.N.C.) (Precedex) (dexmedetomidine) (settled)
• Abbott v. Hospira (D. Del.) (Zemplar) (paricalcitol) (favorable judgment of non-infringement)
• Shire v. Neos (N.D. Tex.) (Adderall XR) (mixed amphetamines) (settled)
• Galderma v. Actavis (N.D. Tex.) (EpiDuo) (adpalene/benzoyl peroxide) (settled)
• Hospira v. Sandoz (D.N.J.) (Precedex) (dexmedetomidine) (settled)
• Hospira v. Sun Pharm. (E.D. Mich.) (Precedex) (dexmedetomidine) (settled)
• Nautilus Neurosciences v. Wockhardt (D.N.J.) (Cambia) (diclofenac sachet) (settled)
• Nautilus Neurosciences v. Edict (D.N.J.) (Cambia) (diclofenac sachet) (settled)
• Shire v. Watson (S.D.N.Y.) (Adderall XR) (mixed amphetamines) (settled) 

Merck & Co., Inc.: Represented the independent directors of Merck in connection with derivative litigation arising out of the marketing and use of Vioxx.

Teva Pharmaceutical Industries Ltd.: Represented Israel-based Teva, the leading generic pharmaceutical company and one of the top 15 pharmaceutical companies in the world, as well as in the following litigation:

• Meijer, Inc. v. Teva Pharmaceutical Industries Ltd.: Secured dismissal for Teva in class action and opt-out litigation seeking treble damages and injunctive relief in connection with allegations that generic drug manufacturers allocated the market for a hypertension drug, resulting in inflated prices.
• Purdue Pharma v. Teva Pharmaceuticals USA.
• Teva Pharmaceutical Industries Ltd. v. SmithKline Beecham Corp.: Successful representation of Teva in suit against SmithKline for prosecuting sham patent infringement litigation in violation of Section 2 of the Sherman Act.

Aegerion Pharmaceuticals/Novelion Therapeutics/ Amryt Pharma Plc.: Represented global biopharmaceutical company Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.

Allergan/Pfizer: Represented Morgan Stanley as financial advisor to Allergan in its agreement to combine with Pfizer for an enterprise value of approximately $160 billion.

Aralez Pharmaceuticals: Represented Aralez Pharmaceuticals in the following M&A-related transactions:

• AstraZeneca: Represented Aralez in its acquisition of the U.S. rights to beta-blocker Toprol-XL® from AstraZeneca.
• Merck: Represented Aralez in its acquisition of the U.S. and Canadian rights to cardiovascular drug Zontivity from Merck.

ARIAD Pharmaceuticals/Takeda/Sarissa Capital Management: Represented Sarissa Capital Management, the largest shareholder of ARIAD Pharmaceuticals, in connection with ARIAD’s agreement to be acquired by Takeda Pharmaceutical Company Limited for approximately $5.2 billion.

Auxilium/Endo International: Represented Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, in its proposed $2.6 billion acquisition by Endo International plc for a combination of cash and stock.

Centerview Partners/Salix Pharmaceuticals: Represented Centerview Partners as financial advisor to Salix Pharmaceuticals, a leader in the gastrointestinal market, in its agreement to be acquired by Valeant Pharmaceuticals for $173 per share or a total enterprise value of approximately $15.8 billion.

Centerview Partners/Tesaro: Represented Centerview Partners as financial advisor to oncology-focused biopharmaceutical company Tesaro in its acquisition by GlaxoSmithKline for $5.1 billion. 

Ekkio Capital/Amatasigroup/Eurofins: Represented Ekkio Capital on the pending sale of Amatsigroup to Eurofins, the world leader in bio-pharmaceutical testing and a world leader in analytical services.

Ekkio Capital/Audevard: Represented Ekkio Capital in its acquisition of Audevard, a veterinary pharmaceutical company focused on the equine field.

Melinta Therapeutics/Cempra, Inc.: Represented Melinta Therapeutics, Inc. and Vatera Healthcare partners, Melinta’s majority shareholder, in Melinta’s agreement to merge with Cempra, Inc., forming a leading, vertically integrated commercial-stage anti-infectives company.

Melinta Therapeutics/Infectious Disease Business of The Medicines Company: Represented Melinta Therapeutics, Inc, in its pending acquisition the infectious disease business from The Medicines Company.

PAI Partners/Ethypharm: Represented PAI Partners in its negotiations to acquire European specialty pharma company Ethypharm from Astorg.

RIEMSER Pharma/Intrapharm Laboratories: Represented RIEMSER Pharma GmbH, a German specialty pharmaceutical company backed by Ardian, in its acquisition of British specialty pharmaceutical company Intrapharm Laboratories Ltd.

RIEMSER Pharma/Keocyt: Advised RIEMSER Pharma GmbH in its acquisition of French specialty pharmaceutical company Keocyt.

Sanofi-Aventis/Hoechst AG: Represented Sanofi-Aventis, the world’s largest pharmaceutical company, in its mandatory offer to shareholders of Hoechst.

Taro Pharmaceutical Industries Ltd.: Served as U.S. legal counsel to the Special Committee of Taro Pharmaceutical Industries Ltd.’s Board of Directors in the merger agreement with Sun Pharma. Both Sun Pharma and Taro (at the direction of the Special Committee) agreed that terminating the merger agreement was in the best interest of the respective companies and shareholders.

Vatera/CVC/Alvogen: We represented Vatera Healthcare Partners as part of the investment consortium led by CVC Capital Partners in the acquisition of a controlling stake in Alvogen, a high-growth pharmaceutical company, from Pamplona Capital Management.

Voalte/Hill-Rom: Represented Voalte, a pioneer and leader in real-time, mobile healthcare communications, in its sale to global medical technology company Hill-Rom for $180 million.

Warburg Pincus: Advised Warburg on numerous M&A-related transactions, including its investments in the following pharmaceutical companies:

• JHP Pharmaceuticals: Represented Warburg in connection with the approximately $490 million sale of JHP Pharmaceuticals, LLC to Par Pharmaceutical Companies.

• The Medicines Company: Advised Warburg in connection with its investment in The Medicines Company, a provider of cost-effective acute care products.

WuXi/Management-Led LBO: Represented the Special Committee of the Board of Directors of WuXi PharmaTech Inc. in its $3.3 billion management-led leveraged buyout, one of the largest going private transactions of a Chinese-based, U.S. listed company.

Genta Incorporated: Provided corporate representation on M&A and senior executive employment matters for the compensation committee of Genta, a biopharmaceutical company with a diversified portfolio of cancer treatment drug products.